CTOs on the Move

Reeves-Sain

www.reevessain.com

 
Reeves-Sain is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

ACell

ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing, and commercialization of unique proprietary extracellular matrix (ECM) products to facilitate the repair and remodeling of damaged tissues. ACell is committed to becoming and remaining an innovative leader in regenerative medical technology, offering superior healing options for doctors and patients. ACell is a privately held company and operates manufacturing facilities in Columbia, MD and Lafayette, IN.

RADinfo SYSTEMS

RADinfo SYSTEMS is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Precision Biopsy

Precision Biopsy, LLC was formed in partnership with Allied Minds to develop and commercialize novel technology for the accurate diagnosis of prostate cancer. The company’s diagnostic technology uses advanced spectroscopy imaging techniques in combination with tissue biopsy. For the first time, this unique ability will eliminate random prostate biopsies that are subject to sampling errors and can lead to inaccurate grading and staging of the disease. The scientific founders, professors Priya Werahara and John Daily of the University of Colorado, have long studied the morphology of cancer tissue. Combining their knowledge of advanced spectroscopy techniques has resulted in the ability to image the precise location of cancer in the prostate.

RxSight

RxSight® is a privately-held corporation headquartered in Aliso Viejo, California that has commercialized the world`s first and only adjustable intraocular lens (IOL) that is customized after cataract surgery.

Vermillion

Vermillion`s vision is to become a recognized leader in the advancement of women`s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases. We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.